Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Behav Brain Res ; 427: 113846, 2022 06 03.
Article in English | MEDLINE | ID: mdl-35306097

ABSTRACT

Mammalian adult females develop specialized body parts, namely mammary glands and uterus, and exhibit specialized maternal behavior, lactation/nursing and care for their offspring. As the brain plays an essential role in regulating related physiological functions in the body, the morphology or function of the mammalian brain has been modified to manage newly equipped structures and functions. However, this evolutionary process is largely unknown. Pou3f2/Brn2 is an evolutionarily remarkable gene as it contains mammal-specific base sequences encoding three stretches of homopolymeric amino acids (polyAAs): poly-glycine (polyG), poly-glutamine (polyQ), and poly-proline (polyP). Previously, we demonstrated that POU3F2 acquisition of mammal-specific polyAAs contributed to the establishment of behaviors characteristic of mammals. Here, we demonstrated that Pou3f2⊿ mice displayed basic features required for maternal care. However, Pou3f2⊿ mice exhibited deficits in the reproductive performance and maternal behavior, which were not fully improved by multiparas. Therefore, we extensively investigated pup retrieval behavior and discovered that the retrieval and the exploratory behaviors were impaired in Pou3f2⊿ female mice, but not in males. Altogether, our data suggest that POU3F2 acquisition of mammal-specific polyAAs contributes to the continuous awareness and curiosity needed for maternal interaction.


Subject(s)
Exploratory Behavior , Maternal Behavior , Animals , Brain/metabolism , Exploratory Behavior/physiology , Female , Humans , Lactation , Male , Mammals , Maternal Behavior/physiology , Mice
2.
Biochem Biophys Res Commun ; 523(2): 411-415, 2020 03 05.
Article in English | MEDLINE | ID: mdl-31870549

ABSTRACT

Pou3f2/Brn2 is a transcription factor that helps to determine the cellular identity of neocortical or hypothalamic neurons. Mammalian Pou3f2 contains three homopolymeric amino acids that are not present in amphibian Pou3f2. These amino acids contribute to monoamine function, which may play specific roles in mammalian development and behavior. Previous work has indicated that Pou3f2⊿ mice, which lack the homopolymeric amino acids, exhibited declined maternal activity and impaired object and spatial recognition. The current study, analyzed weight gain, brain development, home cage activity, social interaction, and response to novel objects in Pou3f2⊿ mice to determine which aspects of behavior were affected by monoamine dysregulation. Compared to their wild type counterparts, Pou3f2⊿ mice showed decreased social interaction and reduced home cage activity during their active phase. However, they showed normal weight gain, brain development, and responses to novelty. These results indicate that monoamine dysregulation in Pou3f2⊿ mice may specifically affect basal activity and social development, without altering non-social motivation.


Subject(s)
Behavior, Animal/physiology , Nerve Tissue Proteins/physiology , POU Domain Factors/physiology , Social Behavior , Animals , Biogenic Monoamines/physiology , Brain/growth & development , Exploratory Behavior/physiology , Hypothalamus/physiology , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neocortex/physiology , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/genetics , Neurons/physiology , POU Domain Factors/chemistry , POU Domain Factors/genetics , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Weight Gain
3.
Int J Mol Sci ; 20(20)2019 Oct 13.
Article in English | MEDLINE | ID: mdl-31614909

ABSTRACT

The use of eyewash solutions in Japan, especially in patients with allergic conjunctivitis and contact lens wearers, has been increasing. Our aim was to investigate how the use of preservative-free eyewash solution in healthy eyes for one month affects corneal safety and ocular surface mucin. We analyzed 42 eyes of 21 individuals (17 males, four females; mean age: 36.1 ± 7.4 years) without ocular allergies, dry eyes, or other ocular diseases through a prospective study. Eyes were randomized to a wash group (group one) and a nonwash follow up group (group two). We evaluated the dry eye-related quality-of-life score (DEQS), tear film breakup time (TBUT), fluorescein staining score, mRNA expression of MUC5AC and MUC16, MUC16 immunohistochemistry, and MUC5AC periodic acid Schiff (PAS) staining. There was a significant decrease in DEQS scores after one month of eyewash use (p < 0.05). There were no significant differences in other evaluation items that were analyzed (all p > 0.05). Furthermore, no significant differences were observed between group one and group two in all endpoints (all p > 0.05). The results suggest that one month use of a nonpreserved eyewash solution has no detrimental effects on the tear film and the ocular surface mucins.


Subject(s)
CA-125 Antigen/metabolism , Conjunctiva/drug effects , Membrane Proteins/metabolism , Mucin 5AC/metabolism , Ophthalmic Solutions/adverse effects , Adult , Conjunctiva/metabolism , Cornea/metabolism , Dry Eye Syndromes/metabolism , Female , Fluorescein/metabolism , Glycyrrhizic Acid/pharmacology , Goblet Cells/cytology , Goblet Cells/metabolism , Humans , Japan , Male , Prospective Studies , Tears/metabolism
4.
Eye Contact Lens ; 44 Suppl 2: S215-S220, 2018 Nov.
Article in English | MEDLINE | ID: mdl-29280750

ABSTRACT

OBJECTIVES: The aim of this study was to assess the safety and efficacy of long-term use of 3% diquafosol ophthalmic solution (DQS), an eye drop for mucin production and water secretion, for treating dry eye disease (DED) caused by chronic graft-versus-host disease (cGVHD). METHODS: We retrospectively evaluated the safety and efficacy of DQS in 10 patients with mild to moderate cGVHD-induced DED. The efficacy was assessed by (1) degree of symptoms, (2) Schirmer I test value, (3) tear film breakup time (TFBUT), and (4) fluorescein and rose bengal scores. RESULTS: The median duration of DQS treatment was 12.0 months (range 6-17 months). DQS was effective for relieving severe pain caused by cGVHD-related DED. Although the Schirmer I test value was enhanced only marginally, the long-term application of DQS significantly improved the corneal/conjunctival epitheliopathy and tear film stability: the fluorescein score improved from 5.9±0.6 to 1.3±1.1 points (P=1.771×10); rose bengal staining from 4.7±1.6 to 2.0±1.5 points (P=0.008); and TFBUT from 2.6±0.9 to 4.6±1.6 mm (P=0.009). Furthermore, the long-term DQS treatment caused no major adverse events. CONCLUSIONS: This study suggested that long-term DQS treatment is a safe and robust approach for alleviating cGVHD-related DED.


Subject(s)
Dry Eye Syndromes/drug therapy , Graft vs Host Disease/complications , Ophthalmic Solutions/administration & dosage , Polyphosphates/administration & dosage , Uracil Nucleotides/administration & dosage , Adult , Aged , Conjunctiva/metabolism , Cornea/metabolism , Cornea/pathology , Dry Eye Syndromes/etiology , Dry Eye Syndromes/physiopathology , Female , Humans , Male , Middle Aged , Mucins/metabolism , Retrospective Studies , Tears/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL